Current advances in sepsis and septic shock with particular emphasis on the role of insulin

Medical Science Monitor

Volumn 9, Issue 8, 2003, Pages

  Das, Undurti N ^a  

^a EFA Sciences LLC   (United States)

Author keywords

Cytokines; Free radicals; Insulin; Myocardium; Nitric oxide; Sepsis; Septic shock

Indexed keywords

ACTIVATED PROTEIN C; ADENOSINE; FREE RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; NITRIC OXIDE; OMEGA 3 FATTY ACID; PHOSPHOLIPID; TUMOR NECROSIS FACTOR ALPHA;

DISEASE ASSOCIATION; ENDOTHELIUM; HEART FUNCTION; HEART MUSCLE; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INTENSIVE CARE; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; REVIEW; SEPSIS; SEPTIC SHOCK; STRESS;

ANTI-INFLAMMATORY AGENTS; CYTOKINES; FREE RADICALS; GLUCOSE; HEART; HUMANS; INSULIN; MACROPHAGE MIGRATION-INHIBITORY FACTORS; NF-KAPPA B; SEPSIS; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141483661     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Angus DC, Linde-Zwirble WT, Lidicker J et al: Epidemiology of severe sepsis in the Unites States: analysis of incidence, outcome and associated costs of care. Crit Care Med, 2001; 29: 1303-1310
2. Das UN: Critical advances in sepsis and septic shock. Crit Care, 2000; 4: 290-294
3. Webb S: The role of mediators in sepsis resolution. Adv Sepsis, 2002; 2: 8-14
4. Abraham E: Why immunomodulatory therapies have not worked in sepsis? Intensive Care Med, 1999; 25: 556-566
5. Calandra T, Echtenacher B, Roy DL et al: Protection from septic-shock by neutralization of macrophage migration inhibitory factor. Nature Med, 2000; 6: 164-170
6. Das UN: Tumor necrosis factor/cachectin: biology and relevance to disease. J Assoc Physicians India, 1991; 39: 201-204
7. Das UN: Free radicals: biology and relevance to disease. J Assoc Physicians India, 1990; 38: 495-498
8. Marchant A, Deviere J, Byl B et al: Interleukin-10 production during sepsis. Lancet, 1994; 343: 707-708
9. Oberholzer A, Oberholzer C, Moldawer LL: Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med, 2002; 30: 58-63
10. Das UN: Transforming growth factor-beta: Is it an endogenous cardioprotector? Med Sci Res, 1993; 21: 373-375
11. Stoiser B, Knapp S, Thalhammer F et al: Time course of immunological markers in patients with the systemic inflammatory response syndrome: Evolution of sCD14, sVCAM-1, sELAM-1, MIP-1 alpha and TGF-beta. Eur J Clin Invest, 1998; 28: 672-678
12. Christ M, McCartney-Francis NL, Kulkarni AB et al: Immune dysregulation in TGF-beta1-deficient mice. J Immunol, 1994; 153: 1936-1946
13. Pinsky MR, Vincent JL, Deviere J et al: Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest, 1993; 103: 565-575
14. Martin C, Boisson C, Haccoun M et al: Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukins-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med, 1997; 25: 1813-1819
15. Foulds S, Galustian C, Mansfield AO, Schachter M: Transcription factor NFκB expression and posrsurgical organ dysfunction. Ann Surg, 2001; 233: 70-78
16. Paterson RL, Galley HF, Dhillon JK, Webster NR: Increased nuclear factor κB activation in critically ill patients who die. Crit Care Med, 2000; 28: 1047-1051
17. Bohrer H, Qiu F, Zimmermann T et al: Role of NFκB in the mortality of sepsis. J Clin Invest, 1997; 100: 972-985
18. Lavon I, Goldberg I, Amit S et al: High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-κB activation. Nature Med, 2000; 6: 573-577
19. Bernard GR, Vincent JL, Laterre PF et al: For the Rcombinant Human Activated Protein C Worldwide Evaluation in severe Sepsis (PROWESS)Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 2001; 344: 699-709
20. Siegel JP: Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med, 2002; 347: 1030-1034
21. Warren HS, Suffredini AF, Eichacker PQ, Munford RS: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med, 2002; 347: 1027-1030
22. Ely EW, Bernard GR, Vincent JL: Activated protein C for severe sepsis. N Engl J Med, 2002; 347: 1035-1036
23. Davidson BL, Geerts WH, Lensing AWA: Low-dose heparin for severe sepsis. N Engl J Med, 2002; 347: 1036-1037
24. Bernard GR, Ely EW, Wright TJ et al: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med, 2001; 27: 104-115
25. Joyce DE, Gelbert L, Ciaccia A et al: Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem, 2001; 276: 11199-11203
26. Leitinger N, Tyner TR, Oslund L et al: Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci USA, 1999; 96: 12010-12015
27. Watson AD, Leitinger N, Navab M et al: Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem, 1997; 272: 13597-13607
28. ++/NFAT. Blood, 2002; 99: 199-206
29. Bochkov VN, Kadl A, Huber J et al: Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature, 2002; 419: 77-81
30. Emancipator K, Csako G, Elin RJ: In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun, 1992; 60: 596-601
31. Hessler JR, Morel DW, Lewis LJ, Chisolm GM: Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis, 1983; 3: 215-222
32. Riedemann NC, Ward PA: Oxidized lipid protects against sepsis. Nature Med, 2002; 8: 1084-1085
33. Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol, 1994; 76: 5-13
34. Flamand N, Boudreault S, Picard S et al: Adenosine, a potent natural suppressor of arachidonic acid and leukotriene biosynthesis in human neutrophils. Am J Respir Crit Care Med, 2000; 161: 88-94
35. 1 biosynthesis by endogenous adenosine in ligand-activated human neutrophils. J Exp Med, 1997; 186; 1401-1406
36. 2A receptor-dependent and independent mechanisms. FASEB J, 2000; 14: 2065-2074
37. Hasko G, Kuhel DG, Nemeth ZH et al: Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol, 2000; 164: 1013-1019
38. Firestein GS, Boyle D, Bullough DA et al: Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol, 1994; 152: 5853-5859
39. Kowaluk EA, Mikusa J, Wismer CT et al: ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyridol [2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. J Pharmacol Exp Ther, 2000; 295: 1165-1174
40. Ohta A, Sitkovsky M: Role of G-protein adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature, 2001; 414: 916-919
41. 2A receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol, 2001; 21: 791-796
42. 2 (Gαs-linked) receptors. J Exp Med, 1997; 186: 1615-1620
43. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA: Possible new role for NF-κB in the resolution of inflammation. Nature Med, 2001; 7: 1291-1297
44. Gilroy BW, Colville-Nash PR, Willis D et al: Inducible cyclo-oxygenase may have anti-inflammatory properties. Nature Med, 1999; 5: 698-701
45. Glauser MP, Zanetti G, Baumgartner JD, Cohen J: Septic shock: pathogenesis. Lancet, 1991; 338: 732-736
46. Byerley LO, Alcock NW, Starnes HF Jr: Sepsis-induced cascade of cytokine mRNA expression: correlation with metabolic changes. Am J Physiol, 1992; 262: 728-735
47. Lang CH, Dobrescu C: In vivo insulin resistance during nonlethal hypermatebolic sepsis. Circ Shock, 1989; 28: 165-178
48. Chambrier C, Laville M, Rhzioual Berrada K et al: Insulin sensitivity of glucose and fat metabolism in severe sepsis. Clin Sci (Colch), 2000; 99: 321-328
49. Maitra SR, Wojnar MM, Lang CH: Alterations in tissue glucose uptake during the hyperglycemic and hypoglycemic phases of sepsis. Shock, 2000; 13: 379-385
50. Patiag D, Gray S, Idris I, Donnelly R: Effects of tumor necrosis factor-alpha and inhibition of protein kinase C on glucose uptake in L6 myoblasts. Clin Sci (Colch), 2000; 99: 303-307
51. Vary TC, Drnevich D, Jurasinski C, Brennan WA Jr: Mechanisms regulating skeletal muscle glucose metabolism in sepsis. Shock, 1995; 3: 403-410
52. Lind L, Lithell H: Impaired glucose and lipid metabolism seen in intensive care patients is related to severity of illness and survival. Clin Intensive Care, 1994; 5: 100-105
53. Spitzer JA, Hastings PR, Leech SH: Insulin receptor antibodies in sepsis. Arch Intern Med, 1984; 144: 2019-1022
54. Holley DC, Spitzer JA: Insulin action and binding in adipocytes exposed to endotoxin in vitro and in vivo. Circ Shock, 1980; 7: 3-12
55. Yelich MR, Filkins JP: Insulin hypersecretion and potentiation of endotoxin shock in the rat. Circ Shock, 1982; 9: 589-603
56. Fan J, Li YH, Wojnar MM, Lang CH: Endotoxin-induced alterations in insulin-stimulated phosphorylation of insulin receptor, IRS-1, and MAP kinase in skeletal muscle. Shock, 1996; 6: 164-170
57. Dahn MS, Lange MP, Mitchell RA et al: Insulin production following injury and sepsis. J Trauma, 1987; 27: 1031-1038
58. Zenni GC, McLane MP, Law WR, Raymond RM: Hepatic insulin resistance during chronic hyperdynamic sepsis. Circ Shock, 1992; 37: 198-208
59. Raymond RM, Harkema JM, Emerson TE Jr: In vivo skeletal muscle insulin resistance during E coli endotoxin shock in the dog. Circ Shock, 1981; 8: 425-433
60. Maitra SR, Wang S, Baithwaite CE, El-Maghrabi MR: Alterations in glucose-6-phosphatase gene expression in sepsis. J Trauma, 2000; 49: 38-42
61. Lang CH, Dobrescu C: Sepsis-induced changes in in vivo insulin action in diabetic rats. Am J Physiol, 1989; 257: 301-308
62. Das UN: Possible beneficial action(s) of glucose-insulin-potassium regimen in acute myocardial infarction and inflammatory conditions: a hypothesis. Diabetologia, 2000; 43: 1081-1082
63. Court O, Kumar A, Parrillo JE, Kumar A: Clinical review: Myocardial depression in sepsis and septic shock. Crit Care, 2002; 6 (DOI 10, 1186)/cc1822)
64. Bronsveld W, van Lambalgen AA, van Velzen D et al: Myocardial metabolic and morphometric changes during canine endotoxin shock before and after glucose-insulin-potassium. Cardiovasc Res, 1985; 19: 455-464
65. Tuynman HA, Thijs LG, Straub JP et al: Effects of glucose-insulin-potassium (GIK) on the position of the oxyhemoglobin dissociation curve, 2, 3-diphosphoglycerate, and oxygen consumption in canine endotoxin shock. J Surg Res, 1983; 34: 246-253
66. Hinshaw LB, Archer LT, Benjamin B, Bridges C: Effects of glucose or insulin on myocardial performance in endotoxin shock. Proc Soc Exp Biol Med, 1976; 152: 529-534
67. Archer LT, Beller BK, Drake JK et al: Reversal of myocardial dysfunction in endotoxin shock with insulin. Can J Physiol Pharmacol, 1978; 56: 132-138
68. Mauritz W, Schindler I, Zadrobilek E, Sporn P: Glucose-potassium-insulin in hypodynamic septic shock. Anaesthesist, 1986; 35: 623-627
69. Bronsveld W, van den Bos GC, Thijs LG. Use of glucose-insulin-potassium (GIK) in human septic shock. Crit Care Med, 1985; 13: 566-570
70. Zhu P, Lu L, Xu Y et al: Glucose-insulin-potassium preserves systolic and diastolic function in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol, 2001; 278: 595-603
71. Rudez I, Sutlic Z, Husedzinovic I et al: The importance of glucose-insulin-potassium with cardiopulmonary bypass prior to cardioplegic arrest in open-heart surgery. Lijed Vjesn, 1995; 117(Suppl2): 105-106
72. Girard C, Quentin P, Bouvier H et al: Glucose and insulin supply before cardiopulmonary bypass in cardiac surgery: a double-blind study. Ann Thorac Surg, 1992; 54: 259-263
73. Lell WA, Nielsen VG, McGiffin DC et al: Glucose-insulin-potassium infusion for myocardial protection during off-pump coronary artery surgery. Ann Thorac Surg, 2002; 73: 1246-1251
74. Bruemmer-Smith S, Avidan MS, Harris B et al: Glucose, insulin and potassium for heart protection during cardiac surgery. Br J Anaesth, 2002; 88: 489-495
75. Rao V, Christakis GT, Weisel RD, for the ICT Investigators et al: The Insulin Cardioplegia Trial: myocardial protection for urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg, 2002; 123: 928-935
76. Diaz-Arya G, Nettle D, Castro P et al: Oxidative stress after reperfusion with primary coronary angioplasty: Lack of effect of glucose-insulin-potassium infusion. Crit Care Med, 2002; 30: 417-421
77. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycemia and increased risk of death artery myocardial infarction in patients with and without diabetes: a systematic overview. Lancet, 2000; 355: 773-778
78. Van den Berghe G, Wouters P, Weckers F et al: Intensive insulin therapy in critically ill. N Engl J Med, 2001; 345: 1359-1367
79. Das UN: Is insulin an endogenous cardioprotector? Crit Care, 2002; 6: 389-393
80. Christiansen CL, Schurizek BA, Malling B et al: Insulin treatment of the insulin-dependent diabetic patient undergoing minor surgery. Continuous intravenous infusion compared with subcutaneous administration. Anaesthesia J, 1988; 43: 533-537
81. Das UN: Is insulin an anti-inflammatory molecule? Nutrition, 2001; 17: 409-413
82. Das UN: Insulin and the critically ill. Crit Care, 2002; 6: 262-263
83. Diaz R, Paolasso FA, Piegas LS et al: Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation, 1998; 98: 2227-2234
84. Van Campen CMC, Klein LJ, Visser FC: Glucose-insulin-potassium imaging: the past and the future? Heart Metabol, 2001; 12: 14-18
85. Jonassen AK, Sack MN, Mjos OD, Yellon DM: Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell survival signaling. Circ Res, 2001; 89: 1191-1198
86. Rao V, Meranta F, Weisel RD et al: Insulin stimulates pyruvate dehydrogenase and protects human ventricular cardiomyocytes from stimulated ischemia. J Thorac Cardiovasc Surg, 1998; 116: 485-494
87. Girard C, Quentin P, Bouvier H et al: Glucose and insulin supply before cardiopulmonary bypass in cardiac surgery: a double-blind study. Ann Thorac Surg, 1992; 54: 259-263
88. Ryan TJ, Antman EM, Brooks NH et al: 1999 update: ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation, 1999; 100: 1016-1030
89. Rogers WJ, Stanley AW Jr, Breinig JB et al: Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion. Am Heart J, 1976; 92: 441-454
90. Marano L, Bestetti A, Lomuscio A et al: Effects of infusion of glucose-insulin-potassium on myocardial function after a recent myocardial infarction. Acta Cardiol, 2000; 55: 9-15
91. Lazar HL, Zhang X, Rivers S et al: Limiting ischemic myocardial damage using glucose-insulin-potassium solutions. Ann Thorac Surg, 1995; 60: 411-416
92. Malmberg K, Ryden L, Efendic S et al: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol, 1995; 26: 57-65
93. Machtey I, Syrkis I, Nissimov MR, Lobel H: Potassium, glucose and insulin administration in acute myocardial infarction: a five year study. J Am Geriatr Soc, 1976; 24: 534-537
94. Malmberg K: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (diabetes mellitus, insulin glucose infusion in acute myocardial infarction) Study Group. BMJ, 1997; 314: 1512-1515
95. Oliver MF, Opie LH: Effects of glucose and fatty acids on myocardial ischemia and arrhythmias. Lancet, 1994; 343: 155-158
96. Giardino I, Edelstein D, Brownlee M: BCL-2 expression or antioxidants prevent hyperglycemia-induced formation intracellular advanced glycation end products in bovine endothelial cells. J Clin Invest, 1996; 97: 1422-1428
97. Laight DW, Kaw AV, Carrier MJ, Anggard EE: Interaction between superoxide anion and nitric oxide in the regulation of vascular endothelial function. Br J Pharmacol, 1998; 124: 238-244
98. Das UN: Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. Mol Cell Biochem, 2000; 215: 145-152
99. Nishikawa T, Edelstein D, Du XL et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature, 2000; 404: 787-790
100. Mohanty P, Hamouda W, Garg R et al: Glucose challenge stimulates reactive oxygen species (ROS) generation by leukocytes. J Clin Endocrinol Metab, 2000; 85: 2970-2973
101. Booth G, Stalker TJ, Lefer AM, Scalia R: Elevated ambient glucose induces active inflammatory events in the microvasculature: effects of insulin. Am J Physiol, 2001; 280: 848-856
102. Dandona P, Aljada A, Mohanty P et al: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect. J Clin Endocrinol Metab, 2001; 86: 3257-3265
103. Aljada A, Saadesh R, Assian E et al: Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab, 2000; 85: 2572-2575
104. Aljada A, Ghanim H, Saadesh R, Dandona P: Insulin inhibits NFκB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab, 2001; 86: 450-453
105. Das UN: Insulin and inflammation: further evidence and discussion. Nutrition, 2002; 18: 526-527
106. Fan J, Frey RS, Rahman A, Malik AB: Role of neutrophil NADPH oxidase in the mechanism of tumor necrosis factor-α-induced NF-κB activation and intercellular adhesion molecule-1 expression in endothelial cells. J Biol Chem, 2002; 277: 3404-3411
107. Guzik TJ, Mussa S, Gastaldi D et al: Mechanisms of increased vascular superoxide production in human diabetes mellitus. Circulation, 2002; 105: 1656-1662
108. Satomi N, Sakurai A, Haranaka K: Relationship of hypoglycemia to tumor necrosis factor production and antitumor activity: role of glucose, insulin, and macrophages. J Natl Cancer Inst, 1985; 74: 1255-1260
109. Fraker DL, Merino MJ, Norton JA: Reversal of the toxic effects of cachectin by concurrent insulin administration. Am J Physiol, 1989; 256(6 Pt 1): 725-731
110. Xing Z, Gauldie J, Cox G et al: IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest, 1998; 101: 311-320
111. Law WR, McLane MP, Raymond RM: Adenosine restores myocardial responsiveness to insulin during acute endotoxin shock in vivo. Circ Shock, 1989; 28: 333-345
112. Li C, Ha T, Browder W, Kao RL: Adenosine prevents activation of transcription factor NF-kappa B and enhances activator protein-1 binding activity in ischemic rat heart. Surgery, 2000; 127: 161-169
113. Nie Z, Mei Y, Ford M et al: Oxidative stress increases A1 adenosine receptor expression by activating nuclear factor kappa B. Mol Pharmacol, 1998; 53: 663-669
114. Combes P, Dickenson JM: Inhibition of NF-kappaB-mediated gene transcription by the human A2B adenosine receptor in Chinese hamster ovary cells. J Pharm Pharmacol, 2001; 53: 1153-1156
115. Prabha PS, Das UN, Ramesh G et al: Free radical generation, lipid peroxidation and essential fatty acids in patients with sepsis. Prostaglandins Leukot Essen Fatty Acids, 1991; 42: 61-65
116. Das UN: Beneficial effect(s) of ωn-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot Essen Fatty Acids, 2000; 63: 351-362
117. Farolan LR, Goto M, Myers TF et al: Perinatal nutrition enriched with omega-3 polyunsaturated fatty acids attenuates endotoxic shock in newborn rats. Shock, 1996; 6: 263-266